CORDStrom™
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Pivotal TrialCompleted
Key Facts
Indication
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase
Pivotal Trial
Status
Completed
Company
About INmune Bio
INmune Bio is pioneering a precision approach to innate immune system modulation, focusing on restoring normal function rather than broad suppression. The company has two late-stage assets with near-term regulatory and pivotal-trial milestones, targeting significant markets in Alzheimer's disease and oncology. Its clinical development strategy emphasizes matching drug mechanism to patient biology and using relevant outcome metrics that prioritize patient benefit.
View full company profile